Sofia R. Bartlett
Sofia R. Bartlett
British Columbia Centre for Disease Control, University of British Columbia
Verified email at kirby.unsw.edu.au - Homepage
Title
Cited by
Cited by
Year
The influence of hepatitis C virus genetic region on phylogenetic clustering analysis
FMJ Lamoury, B Jacka, S Bartlett, RA Bull, A Wong, J Amin, J Schinkel, ...
PloS one 10 (7), e0131437, 2015
462015
Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review
SR Bartlett, J Grebely, AA Eltahla, JD Reeves, AYM Howe, V Miller, ...
Hepatology communications 1 (5), 379-390, 2017
362017
Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project
SR Bartlett, P Fox, H Cabatingan, A Jaros, C Gorton, R Lewis, E Priscott, ...
Clinical Infectious Diseases 67 (3), 460-463, 2018
312018
A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies
SR Bartlett, JO Wertheim, RA Bull, GV Matthews, FMJ Lamoury, ...
Journal of viral hepatitis 24 (5), 404-411, 2017
222017
Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE Study
M Martinello, J Yee, SR Bartlett, P Read, D Baker, JJ Post, R Finlayson, ...
Clinical Infectious Diseases 71 (6), 1502-1510, 2020
10*2020
HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
SR Bartlett, B Jacka, RA Bull, F Luciani, GV Matthews, FMJ Lamoury, ...
Infection, Genetics and Evolution 37, 252-258, 2016
82016
The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals
SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt, S Wong, M Darvishian, ...
Liver International 39 (12), 2261-2272, 2019
72019
Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations
C Rossi, D Jeong, S Wong, G McKee, ZA Butt, J Buxton, J Wong, ...
Journal of hepatology 71 (6), 1116-1125, 2019
72019
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in …
S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ...
Journal of Viral Hepatitis 27 (3), 281-293, 2020
62020
Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies
M Darvishian, S Wong, M Binka, A Yu, A Ramji, EM Yoshida, J Wong, ...
Journal of Viral Hepatitis 27 (3), 243-260, 2020
52020
A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015
SR Bartlett, TL Applegate, BP Jacka, M Martinello, FMJ Lamoury, M Danta, ...
Journal of the International AIDS Society 22 (2), e25222, 2019
42019
Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia
M Martinello, S Bartlett, G Dore, R Bopage, R Finlayson, D Baker, M Bloch, ...
Journal of Hepatology 68, S312-S313, 2018
42018
Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: The potential roles for decriminalization and safe supply
M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall
Journal of studies on alcohol and drugs 81 (5), 556-560, 2020
32020
Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types
FMJ Lamoury, S Bartlett, B Jacka, B Hajarizadeh, J Grebely, GV Matthews, ...
The Journal of molecular diagnostics 17 (5), 583-589, 2015
32015
Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli
S Bartlett, J Seeliger, JN Burnell
Current Topics in Biochemical Research 14, 77-83, 2012
32012
Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: A population-based cohort study
J Wilton, S Wong, A Yu, A Ramji, D Cook, ZA Butt, M Alvarez, M Binka, ...
Open forum infectious diseases 7 (3), ofaa055, 2020
22020
REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AS A HEPATITIS C VIRUS INFECTION SALVAGE TREATMENT
M Krajden, D Cook, S Wong, J Wilton, ZA Butt, S Bartlett, M Pearce, ...
HEPATOLOGY 70, 914A-914A, 2019
22019
SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia
SH Hooshyar, M Martinello, J Yee, S Bartlett, P Read, D Baker, J Post, ...
Journal of Hepatology 70 (1), e734, 2019
12019
Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada
H Samji, A Yu, S Wong, J Wilton, M Binka, M Alvarez, S Bartlett, M Pearce, ...
International Journal of Drug Policy 86, 102989, 2020
2020
Syndemic profiles of people living with hepatitis C virus using population-level latent class analysis to optimize health services
E Clementi, S Bartlett, M Otterstatter, JA Buxton, S Wong, A Yu, ZA Butt, ...
International Journal of Infectious Diseases 100, 27-33, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–20